February 21, 2024

Optimizing Myeloma Treatment: Pomalidomide-based Regimens Compared in Asian Myeloma Network (AMN) Study — a Phase III Analysis of PCd vs. Pd for Relapse or Refractory Myeloma (RRMM)

Wee-Joo Chng, MBBS, PhD, FRCPath, FRCP, (National University Cancer Institute — Singapore) discusses this randomized phase III trial that compares the use of PCd versus Pd in a population of Asian patients with relapsed/refractory multiple myeloma.    

Watch the video now…